Abbott’s growth engine sputters

April 15th, 2009 10:29 AM - (Crain’s) — The torrid growth of Abbott Laboratories’ rheumatoid arthritis drug, Humira, has cooled in recent months, stoking investors’ concerns over how long the blockbuster medication can drive the drugmaker’s profit growth.
North Chicago-based Abbott on Wednesday reported ...<div class="feedflare">
<a href="http://feeds2.feedburner.com/~ff/ChicagobusinesscomBreakingNews?a=ge5bnG7UFj0:AFi4I b7vca8:yIl2AUoC8zA"><img src="http://feeds2.feedburner.com/~ff/ChicagobusinesscomBreakingNews?d=yIl2AUoC8zA" border="0"></img></a> <a href="http://feeds2.feedburner.com/~ff/ChicagobusinesscomBreakingNews?a=ge5bnG7UFj0:AFi4I b7vca8:V_sGLiPBpWU"><img src="http://feeds2.feedburner.com/~ff/ChicagobusinesscomBreakingNews?i=ge5bnG7UFj0:AFi4I b7vca8:V_sGLiPBpWU" border="0"></img></a> <a href="http://feeds2.feedburner.com/~ff/ChicagobusinesscomBreakingNews?a=ge5bnG7UFj0:AFi4I b7vca8:F7zBnMyn0Lo"><img src="http://feeds2.feedburner.com/~ff/ChicagobusinesscomBreakingNews?i=ge5bnG7UFj0:AFi4I b7vca8:F7zBnMyn0Lo" border="0"></img></a>
</div>

Click here to read article.. (http://feedproxy.google.com/~r/ChicagobusinesscomBreakingNews/~3/ge5bnG7UFj0/news.pl)